Imaging-guided immuno-modulation in patients with MCI

Three INMiND partner institutions from two countries (Germany, United Kingdom) are involved in the research activities of this work package. Leader of this work package is Clive HOLMES, head of the Memory Assessment and Research Unit (MARC) at the University of Southampton (United Kingdom).

This work package is based on:

  • a successful history of immunotherapy research examining the long term clinical and neuropathological outcomes of amyloid-β vaccination in AD;

  • clinical studies examining the role of systemic inflammation;

  • animal models of microglial priming and pharmaceutical collaborations between the research groups at the University of Southampton and the Imperaial College regarding the use of novel amyloid (flutemetamol) and TSPO (GE-180) PET imaging ligands in AD subjects (Holmes et al. 2008; Okello et al. 2009; Rinne et al. 2010; Vandenberghe et al. 2010).

The main objectives of this work package are:

  • to implement a clinical study in amyloid-positive patients with amnestic MCI, who have a high likely-hood for conversion into manifest AD

  • to non-invasively follow the effects of immunotherapy by in vivo amyloid and microglial activation PET markers

  • to relate imaging markers with clinical findings

WP9 Related papers


Farde L. Spotlight: TSPO binding may also represent ‘resting’ microglia. Clin Transl Imaging. 2015;3(6):491-492.
Read full paper via ZENODO


Jacobs AH, Tavitian B; INMiND consortium. Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab. 2012;32(7):1393-415.
Read full paper via ZENODO

INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313